AstraZeneca Forms Research Alliance In China For Chronic Kidney Disease
This article was originally published in PharmAsia News
Executive Summary
To bring new treatment for 112 million patients with kidney disease in China, AstraZeneca is establishing a research collaboration with Shenzhen University to discover new medicines for diabetic nephropathy.
You may also be interested in...
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.